68Ga-grazytracer PET/CT Assists in Diagnosing Pseudoprogression Following Immunotherapy in Lung Cancer: a Prospective, Observational Study.

A clinical trial, NCT06608160, is being conducted to evaluate the effectiveness and feasibility of using 68Ga-grazytracer PET imaging to diagnose pseudoprogression in lung cancer patients after immunotherapy. Pseudoprogression is difficult to distinguish using current methods, and this study aims to address this issue by detecting the concentration of granzyme B, which reflects the localization of cytotoxic T cells in the tumor region. The trial is currently recruiting 30 participants and is expected to be completed by December 2025. This research provides valuable insights into improving the diagnosis of pseudoprogression in lung cancer patients undergoing immunotherapy. [Extracted from the article]